12 Best Performing Stocks in the Last 3 Months

Page 7 of 11

5. Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

6-Month Performance: 266.58%

Number of Hedge Fund Holders: 33

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) ranks among the best-performing stocks in the last 3 months. On October 16, Oppenheimer raised its price target on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) from $115 to $250 and kept an Outperform rating.

This decision came after positive topline results from Praxis Precision Medicines, Inc.’s (NASDAQ:PRAX) 3 Essential3 trial of ulixacaltamide for essential tremor (ET), a nervous system condition that causes involuntary shaking, mostly in the hands and arms. There is currently no approved treatment for this condition.

The drug met all endpoints in Study 1 and its pre-specified primary endpoint in Study 2. Ulixacaltamide was generally safe and well-tolerated, showing no serious drug-related side effects.

Oppenheimer expects Praxis Precision Medicines, Inc. (NASDAQ:PRAX) to submit a New Drug Application in early 2026, which could potentially see the drug being launched commercially in 2027 after approval by the FDA.

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders.

Page 7 of 11